Analysts Set CeriBell, Inc. (NASDAQ:CBLL) PT at $32.14

CeriBell, Inc. (NASDAQ:CBLL - Get Free Report) has been assigned a consensus rating of "Buy" from the eight analysts that are covering the firm, MarketBeat.com reports. Eight investment analysts have rated the stock with a buy recommendation. The average 12-month price target among brokers that have issued a report on the stock in the last year is $32.14.

Several research analysts have recently commented on the company. BTIG Research initiated coverage on CeriBell in a report on Tuesday, June 24th. They issued a "buy" rating and a $30.00 price objective on the stock. LADENBURG THALM/SH SH initiated coverage on CeriBell in a research report on Friday, April 4th. They issued a "buy" rating and a $32.00 price target on the stock.

CeriBell Trading Down 3.8%

CBLL stock traded down $0.63 during mid-day trading on Friday, hitting $16.13. 131,165 shares of the stock were exchanged, compared to its average volume of 290,379. The company has a current ratio of 17.36, a quick ratio of 16.81 and a debt-to-equity ratio of 0.11. The business has a fifty day moving average price of $17.52 and a 200 day moving average price of $19.65. CeriBell has a 12 month low of $10.01 and a 12 month high of $32.75.

CeriBell (NASDAQ:CBLL - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.07. The firm had revenue of $20.49 million for the quarter, compared to the consensus estimate of $19.30 million. As a group, equities analysts anticipate that CeriBell will post -2.46 EPS for the current fiscal year.

Insider Activity

In other news, Director Rebecca B. Robertson sold 11,188 shares of the firm's stock in a transaction that occurred on Wednesday, June 18th. The shares were sold at an average price of $17.85, for a total transaction of $199,705.80. Following the transaction, the director directly owned 10,042 shares of the company's stock, valued at approximately $179,249.70. This trade represents a 52.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Xingjuan Chao sold 25,000 shares of the firm's stock in a transaction that occurred on Monday, July 7th. The stock was sold at an average price of $17.70, for a total transaction of $442,500.00. Following the transaction, the chief executive officer directly owned 776,022 shares in the company, valued at approximately $13,735,589.40. This trade represents a 3.12% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 138,333 shares of company stock valued at $2,337,695. 20.10% of the stock is owned by insiders.

Hedge Funds Weigh In On CeriBell

Several institutional investors have recently bought and sold shares of the business. Rhumbline Advisers increased its holdings in CeriBell by 26.5% during the first quarter. Rhumbline Advisers now owns 15,629 shares of the company's stock valued at $300,000 after buying an additional 3,276 shares during the period. Quantbot Technologies LP purchased a new position in CeriBell during the first quarter valued at approximately $175,000. Lord Abbett & CO. LLC increased its holdings in CeriBell by 7.9% during the first quarter. Lord Abbett & CO. LLC now owns 319,501 shares of the company's stock valued at $6,138,000 after buying an additional 23,451 shares during the period. Nuveen LLC purchased a new position in CeriBell during the first quarter valued at approximately $311,000. Finally, Swiss National Bank purchased a new position in CeriBell during the first quarter valued at approximately $467,000.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.